Biden-Harris Administration Secures 66 Million Doses of Moderna's Variant-Specific COVID-19 Vaccine Booster for Potential Use in Fall and Winter 2022 - HHS.gov

The U.S. Department of Health and Human Services (HHS), in collaboration with the U.S. Department of Defense (DOD), today announced an agreement to purchase 66 million doses of Moderna's bivalent COVID-19 vaccine booster candidate for potential use in the fall and winter. This contract announcement follows a recommendation by the FDA last month that vaccine manufacturers update their existing COVID-19 vaccines to create a bivalent booster that can target BA.4 and BA.5 Omicron subvariants.

Today's purchase is in addition to the 105 million bivalent COVID-19 vaccine booster doses the U.S. government purchased recently from Pfizer for potential use later this year, pending FDA authorization and a recommendation by CDC. Pending those FDA and CDC actions, HHS would receive the first deliveries of the Moderna and Pfizer vaccine booster doses in early fall.

"We must stay vigilant in our fight against COVID-19 and continue to expand Americans' access to the best vaccines and treatments," said HHS Secretary Xavier Becerra. "As we look to the fall and winter, we're doing just that—ensuring Americans have the tools they need to stay safe and help keep our nation moving forward."

"We look forward to receiving these new variant-specific vaccines and working with state and local healthcare partners to make the vaccines available for free in communities around the country this fall," said HHS Assistant Secretary Dawn O'Connell who leads the Administration for Strategic Preparedness and Response (ASPR).

Existing COVID-19 vaccines remain the single most important tool in preventing serious illness, hospitalization, and death, and given the current threat that BA.5 Omicron subvariant poses, it is essential that Americans stay up to date with their COVID-19 vaccinations. At the same time, the virus is dynamic, and the Administration continues to act aggressively to ensure that Americans have access to the latest, most protective vaccines as quickly as they become available.

In order to do so in the absence of additional COVID-19 funding from Congress, earlier this month, the Administration was forced to pull $10 billion from critical COVID-19 response efforts in order to pay for additional vaccines and treatments. The funding for this latest agreement with Moderna comes from that reallocated funding.

Combined, the two agreements with Moderna and Pfizer would make available to the U.S. approximately 171 million bivalent vaccine booster doses for the fall and beyond, should they be authorized and recommended, which would not be enough for every single American. Both Moderna and Pfizer agreements include options for a total of 600 million doses—300 million from each company—but these options can only be exercised with additional funding from Congress.

To award the contract, the Biomedical Advanced Research and Development Authority (BARDA), part of ASPR, collaborated with the DOD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and Army Contracting Command.

About HHS, ASPR, and BARDA

HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. ASPR leads HHS in preparing the nation to respond to and recover from adverse health effects of emergencies, supporting communities' ability to withstand adversity, strengthening health and response systems, and enhancing national health security. Within ASPR, BARDA invests in the innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures – vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products – needed to combat health security threats.

About the JPEO-CBRND

The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) protects the Joint Force by providing medical countermeasures and defense equipment against chemical, biological, radiological and nuclear (CBRN) threats. JPEO-CBRND's goal is to enable the Joint Force to fight and win unencumbered by a CBRN environment. JPEO-CBRND facilitates the rapid response, advanced development, manufacturing and acquisition of medical solutions – such as vaccines, therapeutics, and diagnostics – to combat CBRN and emerging threats such as COVID-19. To learn more about JPEO-CBRND's COVID-19 response, visit https://www.jpeocbrnd.osd.mil/coronavirus or follow JPEO-CBRND on social media at @JPEOCBRND.

Adblock test (Why?)

Comments

Post a Comment

Popular posts from this blog

His Apple Watch warned of an irregular heart rate. Turns out he was having a heart attack | Globalnews.ca - Global News Toronto

Image
A Nova Scotia man is thanking a digital watch for saving his life. Travis Chalmers, of Elmsdale, N.S., said he was outside playing road hockey with his son when he suddenly experienced a "warm sensation" in his chest area and a splitting headache. "I just thought it was a flu or cold coming on and my seasonal allergies had been kicking in. I thought it was flu-like symptoms and shrugged it off," he said. But to Chalmers' surprise, an otherwise laidback afternoon eventually took a scary turn when he glanced at his wrist. A notification from his Apple Watch led him to discover he was experiencing a heart attack. "About a half hour later, I'm laying down with my daughter and my heart rate is still beating out of my chest," he continued, adding that he monitored his heart rate on his Apple Watch for the next few hours. The watch indicated that he was experiencing atrial fibrillation, a rapid heart rhythm that can increase the ris...
Read more

“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more

Image
“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more Opioids in America, Part 3: The other side of the crisis - Greeley Tribune Posted: 31 Oct 2020 04:20 PM PDT Editor's Note: This is Part 3 of a three-part series looking into the opioid epidemic across the U.S., rehabilitation options in Weld County and stories from people who have overcome or are currently fighting addiction to opioids. Like many things, there's another side to the opioid crisis. While the addiction to opioids is a problem that needs to be addressed, people who are using the drugs exclusively as prescribed — and who still truly need it from a medical perspective — have been swept up in what some have seen as government's knee-jerk reaction to the crisis. In having their ability limited to get the drugs they need in order to function, many of these patients are left suffering debilitating pain. Richard Mark VanWormer w...
Read more

“A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times” plus 1 more

Image
“A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times” plus 1 more A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times Posted: 12 Dec 2019 11:25 AM PST It was chest pain that brought the 34-year-old woman to the emergency room at Montefiore Medical Center in the Bronx. She'd been coughing for days, but that morning the pain was so bad she was worried that it had turned into pneumonia. She tried to tough it out, but when it was no better by the end of the day, she decided to go to the E.R. It took a few hours, but finally the physician assistant caring for her in the E.R. brought some good news. She didn't have pneumonia; she didn't have a clot in her lungs. This was just muscle strain from coughing. The year before, she was told she had asthma. She was given inhalers to stop the coughing and wheezing, but they didn't seem to do much. So she didn'...
Read more